Novartis Stock Forecast for 2023 - 2025 - 2030
Updated on 05/21/2024
Novartis Stock Forecast and Price Target
The average price target for Novartis's stock of CHF107.62 recently provided by nine leading analysts would represent a 15.26% upside from its last closing price if reached. This potential increase is based on a high estimate of CHF130.01 and a low estimate of CHF81.17. If you are not interested in NOVN stock, you may still be interested in its competitors and their current standings.
15.26% Upside
Novartis Fair Value Forecast for 2023 - 2025 - 2030
Novartis's Price has decreased by 100.00% In the last four years, from CHF77.68 to CHF0.00. For next year, analysts predict Fair Value of CHF97.04, which would mean an increase of 100.00%. Over the next seven years, experts predict that Novartis's Fair Value will grow at a rate of 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$783.18 | Buy/Sell | $636.99 | 12.04% |
ABBV Stock Forecast | AbbVie | Outperform |
9
|
$164.56 | Buy/Sell | $178.42 | 10.90% |
AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£120.96 | Buy/Sell | £165.99 | 34.80% |
ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$103.21 | Buy/Sell | $118.92 | 22.57% |
AMGN Stock Forecast | Amgen | Outperform |
4
|
$314.54 | Buy/Sell | $303.65 | 1.74% |
Novartis Revenue Forecast for 2023 - 2025 - 2030
Novartis's Revenue has decreased by 6.49% In the last three years, from CHF49.90B to CHF46.66B. For next year, analysts predict Revenue of CHF47.74B, which would mean an increase of 2.31%. Over the next seven years, experts predict that Novartis's Revenue will grow at a rate of 8.07%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
EL Stock Forecast | EssilorLuxottica Société ano... | Outperform |
12
|
209.60€ | Buy/Sell | 193.26€ | -1.72% |
CSL Stock Forecast | CSL | Outperform |
12
|
$277.90 | Buy/Sell | $205.51 | -26.07% |
BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$43.36 | Buy/Sell | $58.15 | 24.54% |
Novartis Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Novartis's Dividend per Share has grown by 15.63%, rising from CHF3.39 to CHF3.92. The next year, 16 experts forecast that Novartis's Dividend per Share will decrease by 3.83%, reaching CHF3.77. Over the next seven years, experts predict that Novartis's Dividend per Share will grow at a rate of 2.70%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$237.13 | Buy/Sell | $284.47 | 18.08% |
4568 Stock Forecast | Daiichi Sankyo Company | Buy |
4
|
¥5.53k | Buy/Sell | ¥5.24k | 7.58% |
MMM Stock Forecast | 3M | Hold |
10
|
$105.21 | Buy/Sell | $109.39 | -1.63% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BAS Stock Forecast | BASF | Outperform |
12
|
49.26€ | Buy/Sell | 49.50€ | 13.68% |
ALC Stock Forecast | Alcon | Outperform |
8
|
CHF80.08 | Buy/Sell | CHF90.64 | 20.97% |
CTVA Stock Forecast | Corteva | Outperform |
12
|
$56.74 | Buy/Sell | $61.72 | 14.56% |
Novartis EBITDA Forecast for 2023 - 2025 - 2030
Novartis's EBITDA has grown In the last three years, rising from CHF16.97B to CHF17.52B – a growth of 3.25%. In the next year, analysts believe that EBITDA will reach CHF18.97B – an increase of 8.29%. For the next seven years, experts predict that Novartis's EBITDA will grow at a rate of 23.92%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BIIB Stock Forecast | Biogen | Outperform |
10
|
$231.58 | Buy/Sell | $299.62 | 24.58% |
DD Stock Forecast | DuPont de Nemours | Outperform |
17
|
$79.87 | Buy/Sell | $75.38 | 3.92% |
BAYN Stock Forecast | Bayer | Hold |
5
|
28.67€ | Buy/Sell | 45.15€ | 4.64% |
Novartis EBIT Forecast for 2023 - 2025 - 2030
Novartis's EBIT has seen impressive growth In the last three years, rising from CHF12.19B to CHF12.64B – a growth of 3.73%. In the next year, analysts believe that EBIT will reach CHF17.57B – an increase of 38.98%. For the next seven years, the forecast is for EBIT to grow by 46.37%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
CHD Stock Forecast | Church & Dwight Co Inc | Hold |
11
|
$106.51 | Buy/Sell | $96.90 | 1.40% |
ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$150.24 | Buy/Sell | $245.24 | 44.77% |
4503 Stock Forecast | Astellas Pharma | Outperform |
18
|
¥1.51k | Buy/Sell | ¥2.64k | 32.32% |
Novartis EPS Price Prediction Forecast for 2023 - 2025 - 2030
Novartis's EPS has decreased by 100.00% In the last four years, from CHF5.78 to CHF0.00. For next year, analysts predict EPS of CHF7.22, which would mean an increase of 100.00%. Over the next seven years, experts predict that Novartis's EPS will grow at a rate of 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$77.05 | Buy/Sell | $111.56 | 43.41% |
CIPLA Stock Forecast | Cipla | Outperform |
18
|
Rp1.40k | Buy/Sell | Rp1.43k | 9.72% |
4523 Stock Forecast | Eisai | Outperform |
18
|
¥6.66k | Buy/Sell | ¥9.58k | 26.22% |